BioXcel Therapeutics公司:Igalmi适应症扩展提交时间表支持其最早于2026年底前获得潜在批准

美股速递
Jan 20

BioXcel Therapeutics公司近期公布的提交时间表显示,其药物Igalmi的适应症扩展申请有望最早在2026年底前获得监管批准。这一时间规划为该公司核心产品的市场拓展提供了明确的路线图。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10